Acrivon Therapeutics, Inc. develops drugs for clinical treatment. The company is headquartered in Watertown, Massachusetts and currently employs 75 full-time employees. The company went IPO on 2022-11-15. The company uses its precision Generative Phosphoproteomics platform, Acrivon Predictive Precision Proteomics (AP3), to develop its pipeline of oncology drug candidates. Its lead candidate, ACR-368, is a selective small molecule inhibitor which targets CHK1 and CHK2 at sub single-digit nM and single-digit nM potency in intact cells, respectively, in a registrational Phase II trial across multiple solid tumor types. Using its AP3 platform, it has developed a predictive OncoSignature test for ACR-368, called ACR-368 OncoSignature, that can predict patient response to ACR-368 monotherapy and therefore improve the clinical overall response rate (ORR) and has the potential to enable drug development. Its preclinical program, ACR-2316, is advancing in investigational new drug-enabling studies. The company is a novel, dual WEE1 and PKMYT1 inhibitor small molecule development candidate.
Follow-Up Questions
Acrivon Therapeutics Inc 'in CEO'su kimdir?
Dr. Peter Blume-Jensen 2018 'den beri şirketle birlikte olan Acrivon Therapeutics Inc 'in Chairman of the Board 'ıdır.
ACRV hissesinin fiyat performansı nasıl?
ACRV 'in mevcut fiyatı $1.58 'dir, son işlem günde 5.32% decreased etti.
Acrivon Therapeutics Inc için ana iş temaları veya sektörler nelerdir?
Acrivon Therapeutics Inc Biotechnology endüstrisine ait ve sektör Health Care 'dir
Wall Street analistlerine göre, 8 analist Acrivon Therapeutics Inc için analist derecelendirmeleri gerçekleştirdi, bunlar 4 güçlü al, 9 al, 2 tut, 0 sat ve 4 güçlü sat içermektedir
